SARS-CoV-2 is a deadly enemy; we exploit a key weakness in SARS-CoV-2 to prevent and treat COVID-19.
SARS-CoV-2 binds to a receptor, called ACE II, present on human lung cells. We have designed a new drug delivery vehicle that binds to the same receptor--blocking COVID-19 from entering lung cells. At the same time that our delivery vehicle prevents SARS-CoV-2 from causing infection, it delivers a genomic cocktail that interrupts and prevents COVID-19 replication. As a result, our platform can both prevent and treat COVID-19. For many patients who are immunocompromised, with blood cancers, or other chronic conditions that cannot be vaccinated, our approach provides a viable way to prevent disease and treat it.
Key Advantages: -- Active against all variants. Our genomic cargo targets key elements of SARS-CoV-2 that are present in all variants to date -- Treats the most vulnerable, including those who are deeply immunocompromised for which vaccines aren't an option -- Both a prevention and treatment strategy in one single therapeutic entity -- Rapidly deployable in low medical resource environments that have been historically underserved
Future Pipeline An Agile Pandemic Preparedness Platform SARS-CoV-2 has demonstrated how interconnected the world, and each and every one of us, truly are. Our delivery technology can be rapidly adapted with new cargoes designed to prevent and treat emerging respiratory viruses when they are first detected. This agile tool will be a key part of the world's defenses against emerging pandemics.
A Tool In the Fight Against Pulmonary Malignancies Our delivery platform can be optimized to carry genomic medicines that are capable of treating lung cancer, and unleashing the full power of the body's own immune system to destroy lung tumors.
NANO RED is funded by the National Science Foundation through a Phase I SBIR grant to develop this powerful technology.